Starpharma Holdings
Market Cap
AU$482.4m
Last Updated
2019/12/10 10:32 UTC
Data Sources
Company Financials +
Executive Summary
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has Starpharma Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SPL has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-3.0%
SPL
-6.4%
AU Pharmaceuticals
-1.8%
AU Market
1 Year Return
-9.4%
SPL
-27.7%
AU Pharmaceuticals
20.0%
AU Market
Return vs Industry: SPL exceeded the Australian Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: SPL underperformed the Australian Market which returned 20% over the past year.
Shareholder returns
| SPL | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.0% | -6.4% | -1.8% |
| 30 Day | 6.1% | -13.9% | -0.3% |
| 90 Day | 15.6% | -17.3% | 1.1% |
| 1 Year | -9.4%-9.4% | -27.5%-27.7% | 25.9%20.0% |
| 3 Year | 81.1%81.1% | -40.4%-40.9% | 36.0%17.4% |
| 5 Year | 191.0%191.0% | -17.4%-24.7% | 62.5%25.9% |
Price Volatility Vs. Market
How volatile is Starpharma Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
What Did Starpharma Holdings Limited's (ASX:SPL) CEO Take Home Last Year?2 weeks ago | Simply Wall St
Starpharma Holdings Limited's (ASX:SPL) Path To Profitability1 month ago | Simply Wall St
Introducing Starpharma Holdings (ASX:SPL), A Stock That Climbed 78% In The Last Five YearsValuation
Is Starpharma Holdings undervalued compared to its fair value and its price relative to the market?
11.35x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: SPL (A$1.3) is trading above our estimate of fair value (A$0)
Significantly Below Fair Value: SPL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SPL is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: SPL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SPL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SPL is overvalued based on its PB Ratio (11.4x) compared to the AU Pharmaceuticals industry average (2.8x).
Next Steps
Future Growth
How is Starpharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
72.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: SPL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SPL's is expected to become profitable in the next 3 years.
Revenue vs Market: SPL's revenue (67.6% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: SPL's revenue (67.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SPL's Return on Equity is forecast to be very high in 3 years time (82.7%).
Next Steps
Past Performance
How has Starpharma Holdings performed over the past 5 years?
9.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPL is currently unprofitable.
Growing Profit Margin: SPL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPL is unprofitable, but has reduced losses over the past 5 years at a rate of 9.6% per year.
Accelerating Growth: Unable to compare SPL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.1%).
Return on Equity
High ROE: SPL has a negative Return on Equity (-33.62%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Starpharma Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: SPL's short term assets (A$47.8M) exceed its short term liabilities (A$6.4M).
Long Term Liabilities: SPL's short term assets (A$47.8M) exceed its long term liabilities (A$38.0K).
Debt to Equity History and Analysis
Debt Level: SPL is debt free.
Reducing Debt: SPL has not had any debt for past 5 years.
Balance Sheet
Inventory Level: SPL has a low level of unsold assets or inventory.
Debt Coverage by Assets: SPL's debt is not covered by short term assets (assets are -4346.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SPL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Starpharma Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate SPL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SPL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SPL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
What is the CEO of Starpharma Holdings's salary, the management and board of directors tenure and is there insider trading?
8.2yrs
Average board tenure
CEO
Jackie Fairley (56yo)
13.4yrs
Tenure
AU$1,743,377
Compensation
Dr. Jacinth K. Fairley, also known as Jackie, B.Sc., B.V.Sc.(Hons), MBA, GAICD, FTSE has been the Chief Executive Officer of Starpharma Holdings Limited since July 1, 2006 and serves as its Managing Direct ...
CEO Compensation Analysis
Compensation vs Market: Jackie's total compensation ($USD1.19M) is above average for companies of similar size in the Australian market ($USD699.00K).
Compensation vs Earnings: Jackie's compensation has increased whilst the company is unprofitable.
Board Age and Tenure
8.2yrs
Average Tenure
65yo
Average Age
Experienced Board: SPL's board of directors are considered experienced (8.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 19,046,000 |
| Max Price | AU$1.25 |
| Entity | Company |
| Shares | 2,247,594 |
| Max Price | AU$1.67 |
| Entity | Company |
| Shares | 6,638,250 |
| Max Price | AU$4.01 |
| Entity | Company |
| Shares | 737,642 |
| Max Price | AU$1.15 |
| Entity | Company |
| Shares | 956,045 |
| Max Price | AU$1.33 |
| Entity | Company |
| Shares | 172,604 |
| Max Price | AU$1.12 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 30,000 |
| Max Price | AU$0.96 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, MD & Executive Director |
| Shares | 30,000 |
| Max Price | AU$0.93 |
| Entity | Individual |
| Role | Chairman of the Board Independent Chairman |
| Shares | 50,000 |
| Max Price | AU$0.96 |
| Entity | Company |
| Shares | 298,792 |
| Max Price | AU$1.40 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Jackie Fairley (56yo)
CEO, MD & Executive Director
- Tenure: 13.4yrs
- Compensation: AU$1.74m
Nigel Baade
CFO & Company Secretary
- Tenure: 10.9yrs
- Compensation: AU$551.37k
Board Members
Jackie Fairley (56yo)
CEO, MD & Executive Director
- Tenure: 13.4yrs
- Compensation: AU$1.74m
Dick Hazleton (77yo)
Independent Non-Executive Director
- Tenure: 13yrs
- Compensation: AU$74.50k
Peter Turvey
Independent Non-Executive Director
- Tenure: 7.8yrs
- Compensation: AU$75.50k
Rob Thomas (74yo)
Independent Chairman
- Tenure: 5.5yrs
- Compensation: AU$130.00k
Zita Peach (54yo)
Independent Non Executive Director
- Tenure: 8.2yrs
- Compensation: AU$75.50k
Company Information
Starpharma Holdings Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Starpharma Holdings Limited
- Ticker: SPL
- Exchange: ASX
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$482.366m
- Shares outstanding: 372.48m
- Website: https://starpharma.com
Location
- Starpharma Holdings Limited
- 4-6 Southampton Crescent
- Abbotsford
- Victoria
- 3067
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SPHR.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Sep 2000 |
| SPL | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Sep 2000 |
| PQ6 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Sep 2000 |
| SPL | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Sep 2000 |
| SPHR.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Jan 2005 |
Biography
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/10 10:32 |
| End of Day Share Price | 2019/12/10 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.